Release No. 146
• In general improve ART success rates – to the benefit of mother and child - by adding active components to the media
‘CryoSperm™ is free from human serum albumin, thereby eliminating a concern for transmission of animal or human derived diseases’, says Executive Vice President Sales and Marketing, Mr. Steen Thaarup. The product is developed by Drs Grizard, Prof. Le Lannou and Prof. Boucher from France, and data show a better clinical performance compared to the existing product available.
MediCult’s CEO, Jesper Funding Andersen, adds, ‘the launch of CryoSperm™ fits nicely in our strategy to continuously shift our assortment towards more advanced speciality products. This ensures the clinics better performance and MediCult better earnings as new advanced media are typically priced higher than comparable older products’. CryoSperm™ belongs to the important group of cryopreservation products, of which MediCult is regarded as a global market leader.
For further information, please contact
Jesper Funding Andersen
tel.: +45 46790215
NOTES TO EDITOR
About In Vitro Fertilization
During the last decades in vitro fertilization (IVF) has become an increasingly important way of helping childless couples to a baby of their own. Several additional techniques have been implemented to increase the pregnancy rate. Still the chance of a couple to take home a baby after one IVF treatment is only 25% on average, but with a considerable dispersion due to several factors related to the patient as well as the IVF centre. To increase this figure the traditional way is to increase the number of embryos transferred. This, however, also leads to the birth of multiplets with possible associated medical, social and economical problems. As a consequence of this, the trend today is to improve the treatment methods with the aim of transferring fewer embryos and still maintain or even improve the chances of a pregnancy. An important part of this is the development of improved culture media, which to a higher degree mimic the conditions in vivo. Such media are used during insemination and culture of embryos irrespective of whether the eggs have been matured in vitro (IVM ®) or in vivo using hormone treatment.
About MediCult a/s
MediCult a/s is a leader in the development and commercialization of innovative media products for use in assisted reproduction. The company was founded in 1987 based on a pioneering technique using a patented serum replacement. MediCult is located in Jyllinge, Denmark, and distributes its products worldwide.
MediCult is determined to create shareholder value by playing a significant role in the improvement of infertility treatment. MediCult has defined three key objectives:
• IVM should develop into a first option treatment for many patients groups Single Embryo Transfers (SET) must over time become the standard procedure within assisted reproduction
MediCult is listed on the Oslo Stock Exchange (MEC). For further information, please visit www.medicult.com